More Bad News for Stein Mart, Inc. (NASDAQ:SMRT)

Stein Mart, Inc. (NASDAQ:SMRT)

Stein Mart, Inc. (NASDAQ:SMRT) shares are down over 5% in early trading but have rebounded from the day’s lows after the company released their Q2 financial results. Trading volume is moderately heavy. Importantly, there is a large short-selling position which accounts for over 25% of the stock’s float.

Stein Mart, Inc. (NASDAQ:SMRT)
One month stock price chart for SMRT

The drop in shares of Stein Mart, Inc. (NASDAQ:SMRT) was motivated by a reported decrease in total sales of 2.7% while comparable store sales decreased 5.0 %. Those sales resulted in a loss of (-$0.28) per diluted share of $0.28 compared to diluted earnings per share of $0.06 in 2016. Average store inventories were posted at 15 percent lower than at the same time last year.

Headquartered in Jacksonville, Florida, Stein Mart, Inc. (NASDAQ:SMRT) is a national clothing and household product retailer. Stein Mart offer an experience that is more upscale than other discount retailers, with a focus on ease-of-shopping, service and presentation of merchandise by category, brand, style and size. Stein Mart’s target customer is both style conscious and value seeking with above-average household income. Stein Mart operates nearly 300 stores in 31 states.

Stein Mart, Inc. (NASDAQ:SMRT) was trading north of $12 in 2015 but the shares have been in freefall since late 2016. YTD SMRT stock is down over 77% and down over 85% for the year. Shares are receiving support at the $1 level. Sales have marginally improved over the years but have been flat the last two years at $1.36 billion. Meanwhile there was a major drop in earnings per share. In 2015 EPS was $0.60, then for 2016 it was $0.52. Those figures were followed by an EPS of just $0.01 for 2017.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $SMRT and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Netlist, Inc. (NASDAQ:NLST) Tanks

Netlist, Inc. (NASDAQ:NLST)

Netlist, Inc. (NASDAQ:NLST) stock is down almost 30%, to $0.60, at the opening of the market on a volume figure that indicates trading at over 127 times the daily average. Traders are reacting to the company’s pricing of its public offering of 8.5 million shares of its common stock at a price of $0.60 per share. Netlist has also granted the underwriters a 30-day option to purchase an additional 1.275 million shares of its common stock at $0.60 per share if the need arises to cover any over-allotments. The offering is expected to close on or about August 22, 2017.

Netlist, Inc. (NASDAQ:NLST)
One month stock price chart for NLST

The total gross proceeds are expected to be approximately $5.1 million. After deducting expenses, the net proceeds are expected to be approximately $4.5 million (assuming no exercise of the underwriters’ over-allotment option). The net proceeds will be used by Netlist, Inc. (NASDAQ:NLST) for general corporate purposes, including working capital and other general and administrative purposes.

The current slide in the price of NLST began on August 10, after Netlist, Inc. (NASDAQ:NLST) released Q2 2017 financials. The company’s net loss for the second quarter ended July 1, 2017, was (-$3.8) million, or (-$0.06) loss per share, compared to a net loss for the same period in the prior year of (-$1.5) million, or (-$0.03) loss per share. The slide has continued through the announcement of the dilutive public offering as NLST shares have hit new 52-week lows, eclipsing the old low of $0.83.

Irvine, CA-based Netlist, Inc. (NASDAQ:NLST) is a global provider of high-performance modular memory subsystems to original equipment manufacturers. Netlist specializes in hybrid memory – the merging of DRAM and NAND flash raw materials to create memory solutions. The Company’s patented memory technologies claims to supply superior performance, and high density in a cost-efficient solution.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $NLST and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Singlepoint Inc (OTCMKTS:SING) Drops

Singlepoint Inc (OTCMKTS:SING)

Singlepoint Inc (OTCMKTS:SING) stock lost 17.5% today to close at $0.0693 on a volume figure in excess of 46 million. The loss was surprising given the announcement of a publication’s editorial featuring SinglePoint, Inc. (OTCMKTS:SING). The Network News Wire (NNW) publication focused on Singlepoint’s strengthening position in the legal cannabis industry through the acquisition of, or investment in, small to mid-sized cannabis companies. The publication is titled, “Record Bitcoin Gains Indicate High Times Ahead for Cannabis Cryptocurrency,”. The editorial’s content discusses the potential of cryptocurrencies, such as Bitcoin or Ethereum, to serve as a solution for the cannabis sector’s inability to access the traditional banking system.

Singlepoint Inc (OTCMKTS:SING) has grown from a full-service mobile technology provider to a publicly traded holding company. Through diversification into horizontal markets, Singlepoint Inc (OTCMKTS:SING) is building its portfolio by acquiring interests in undervalued subsidiaries, thereby diversifying its potential revenue base. Through its subsidiary company, SingleSeed, the company is providing products and services to the cannabis industry.

While addressing Singlepoint’s cryptocurrency entry, the editorial stated “”SinglePoint’s bitcoin application will be KYC-AML compliant. Customers will be able to sign up for an account online prior to visiting a merchant, or they can do it in seconds right at the point of sale. Similar solutions have been deployed internationally, but SinglePoint is in an early-mover position to bring such technology to the United States. Though still a few months from its beta launch for the solution, SinglePoint is already amassing potential customers through its website.”

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $SING and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Investors Weigh News from RADA Electronics Ind. Ltd. (NASDAQ:RADA)

RADA Electronics Ind. Ltd. (NASDAQ:RADA)

RADA Electronics Ind. Ltd. (NASDAQ:RADA) shares are up 8% at 12:30PM EST to $2.40 after the company announced receiving an initial order for dozens of Multi-Mission Hemispheric Radars (MHR). The amount is for over $8 million which is more than 50% of all last year’s sales. The order is expected to be filled before the end of this year.

RADA Electronic Ind. Ltd. (NASDAQ:RADA)
One month stock price chart for RADA

Dov Sella, RADA’s CEO, commented, “This is a true breakthrough and highly significant order for RADA. Furthermore, strategically, it is our first delivery to a key US military customer, with potential for further orders down the road. We have been awarded with this order following long, demanding and detailed trials, as would be expected for a key defense application, proving the superiority of our radars in the increasingly important field of counter-UAV warfare.”

One week ago, RADA Electronics Ind. Ltd. (NASDAQ:RADA) announced their Q2 2017 financial results. RADA Q2 revenues were posted at $5.3 million, up 94% compared to the same period last year. Q2 gross Profit totaled $1.7 million versus gross profit of $0.2 million in Q2 2016. Operating income was $0.5 million in Q2 2017 compared to an operating loss of $1 million for the same period of 2016. Net income attributable to RADA’s shareholders in the second quarter of 2017 was $0.5 million, or $0.02 per share, compared with a net loss of $1.6 million, or $0.13 per share, in the second quarter of 2016. The market has responded favorably to the financial results and RADA stock has risen in value since the announcement.

RADA Electronics has a market capitalization of just $50 million which may be the reason that the company is not covered by any analysts. However, shares of RADA Electronic Ind. Ltd. (NASDAQ:RADA) have performed extremely well. YTD RADA stock is up over 91% and up over 97% for the year. RADA shares today hit a new 52-week high, sending the stock’s Relative Strength Index (RSI) to 71.13 which, most experts agree, places the shares barely in “overbought” territory.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $RADA and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Cerecor Inc (NASDAQ:CERC) Announces Three Big News Items

Cerecor Inc (NASDAQ:CERC)

Cerecor Inc (NASDAQ:CERC) shares are the subject of several different news stories and are marginally up at noon EST. Over 1.5 million shares have traded hands which is much higher than their 30-day, daily average of 823,000. Today the biotech company announced Q2 financials, a $25 million rights sale to its CERC-501 treatment, and the retirement of its CEO.

Cerecor Inc (NASDAQ:CERC)
One month stock price chart for CERC.

Cerecor Financials

Cerecor Inc (NASDAQ:CERC) reported a Q2 2017 net loss of (-$1.8) million, or (-$0.14) per share compared to a net loss of (-$3.5) million, or (-$0.41) per share, for the same period in 2016. Q2 2017 Research and development expenses decreased to $0.5 million, compared to $2.5 million for Q2 2016. This decrease was driven primarily by the completion of Cerecor’s Phase 2 clinical trials for CERC-301 and CERC-501 in late 2016. General and administrative expenses for Q2 2017 decreased to $1.4 million, versus $1.6 million for Q2 of 2016. This decrease was driven primarily by a reduction in overall operations due to Cerecor’s limited cash position. As of June 30, 2017, cash and cash equivalents were $5.5 million and current liabilities were $1.7 million.

Today Cerecor Inc (NASDAQ:CERC) also announced that it sold all of its rights to CERC-501 to Janssen Pharmaceuticals, Inc. for $25 million. $3.75 million of that sum was deposited into a 12-month escrow account to secure future indemnification obligations to Janssen, as well as a possible $20 million regulatory milestone payment.

CERC-501 is an oral kappa opioid receptor antagonist that Cerecor developed as an adjunctive treatment of major depressive disorder (“MDD”) and for substance use disorders. CERC-501 has been observed to have activity in animal models of depression, substance withdrawal and dependence, and has been generally well-tolerated in five human clinical trials.

Cerecor CEO News

Lastly, today Cerecor Inc (NASDAQ:CERC) announced the retirement of Dr. Uli Hacksell, Cerecor’s President and CEO, effective Monday, August 14, 2017. John Kaiser, Chief Business Officer, has been appointed Interim CEO. Cerecor’s Board of Directors has initiated a search for a permanent Chief Executive Officer. Dr. Hacksell will stay on as Chairman of Cerecor’s Board.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CERC and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Arcadia Biosciences Inc (NASDAQ:RKDA) Rallies on Financial Release

Arcadia Biosciences Inc (NASDAQ:RKDA)

Shares of Arcadia Biosciences Inc (NASDAQ:RKDA) edged higher by 15.66% after the company reported better than expected second quarter earnings. Investors bought up the shares after the company released financial results that showed revenue growth coupled with declining operating costs and declining net loss.

Arcadia Biosciences Inc (NASDAQ:RKDA)
One month RKDA stock price chart

Stock Performance

Thursday’s rally saw the stock power to highs of $0.60 a share before retreating to the $0.48 mark. The stock faces strong resistance around the $0.50 level.

Arcadia Biosciences Inc (NASDAQ:RKDA) stock is trading 15% below its 50 day moving average as sellers continue to pressure the shares. Arcadia Biosciences Inc. (NASDAQ:RKDA) has underperformed the overall market ever since it started sliding late last year when it was trading at highs of $1.50 a share.

Arcadia Biosciences Inc (NASDAQ:RKDA) is an agricultural biotechnology company. The company develops a portfolio of yield enhancement techniques and traits for addressing multiple crops for supplying global food and feed markets. Partners utilize the firm’s yields to develop higher yield seeds for crops including wheat, rice, soya bean, and corn.

The Davis California Company says it generated revenues of $991,000 in Q2, representing a 37%, increase from Q2 2016. The Company attributes the increase to higher product sales as well as higher contract and grant revenue.

Arcadia Biosciences Inc (NASDAQ:RKDA) second quarter net loss dropped to (-$4) million from (-$4.6) million as of last year. Net loss for the first six months of the year dropped 16% to (-$8.2) million compared to (-$9.7) million as of last year.

“Our positive momentum from the first quarter continued in the second quarter with increased revenue, decreased operating costs and a reduced net loss. Together with our global partners, we continue to advance the key products from our yield trait and food ingredient platforms toward commercialization,” said CEO Raj Ketkar.

The company exited the second quarter with cash and cash equivalent of $44.1 million.

Dow AgroSciences Partnership

Separately, Arcadia Biosciences Inc. (NASDAQ:RKDA) and Dow AgroSciences LLC have entered into a partnership for the development and commercialization of improved wheat quality. The partnership will leverage Arcadia Biosciences non-GM TILLING trait development platform with Dow enabling technology platforms

The collaboration according to Arcadia Biosciences Inc (NASDAQ:RKDA) CEO underscores the company’s commitment to pursuing opportunities in the growing market of improved nutrition traits.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $RKDA and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Enphase Energy Inc (NASDAQ:ENPH) Stock Rallies on CEO Resignation

Enphase Energy Inc (NASDAQ:ENPH)

Enphase Energy Inc (NASDAQ:ENPH) stock rallied 4.27% after the company announced the resignation of current CEO, Paul Nahi. The rally also came after the company reported a smaller than expected second quarter net loss.

Enphase stock price chart:

Enphase Energy Inc (NASDAQ:ENPH)
One month Enphase stock price chart

Enphase Stock Performance

Enphase Energy Inc (NASDAQ:ENPH) shares face a lot of uncertainty in the market even after the brief rally. Enphase stock had initially powered to highs of $1.10 a share, before retreating to $0.928 a share. A bearish tone appears to be building on the stock as investors continue to react to Q2 net loss and imminent management changes.

The company bills itself as a leading provider of energy management solutions. Enphase Energy Inc (NASDAQ:ENPH) designs, develops and manufactures micro inverter systems for the solar photovoltaic industry. The global energy technology company also delivers smart easy to use solutions for connecting solar generation storage management solutions on one intelligent platform.

Enphase Q2 Earnings Report

Enphase Energy Inc (NASDAQ:ENPH) says it generated total revenues of $74.7 million for the three months ended June 30, 2017, representing a 36% year over year increase. Gross margin in the quarter dropped to 18.1% from 18.9% as of last year. GAAP operating expense dropped 22% to $22.8 million.

Net loss for the quarter dropped to (-$12.1) million from (-$16.7) million reported in Q2 2016. Enphase energy generated a total of $1 million in cash in the quarter to exit with a total cash balance of $31 million.

“We believe the combination of operating expense reduction, supply chain optimization and the transition to our sixth-generation IQ Microinverter System will enable us to achieve non-GAAP operating income profitability by the fourth quarter of 2017,” said Bert Garcia, CFO of Enphase Energy Inc (NASDAQ:ENPH).

For the third quarter, Enphase Energy says it expects revenues of between $72 million and $80 million which should lead to a gross margin of between 18% and 21%.

CEO Appointment

Enphase Energy Inc (NASDAQ:ENPH) has also confirmed that it has started the process of recruiting a new CEO following the resignation of Mr. Nahi.

“It has been an enormous privilege to lead Enphase since inception and through its growth to become a leading global energy technology company,” said Paul Nahi

Following Mr. Nahi resignation, Enphase Energy Inc (NASDAQ:ENPH) board of directors has appointed Bert Garcia, CFO, and Badri Kothandaraman, COO to oversee and provide leadership pending appointment of new CEO probably before August 31, 2017.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ENPH and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Why Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Stock Broke Resistance

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) stock price is up over 22% after the biotechnology company announced positive interim results for its drug candidate, ACH-4471. Also today the company reported financial results for the most recent quarter and six months. By 12:40 PM EST, ACHN shares had a volume of over 20 million shares, far exceeding their daily average of 1.5 million.

As of market close yesterday, ACHN shares were down YTD, but after news of the interim clinical trial results, ACHN stock gapped up to open at $4.70 then proceeded to blast through resistance just above $5.00. Shares of ACHN then hit an inter-day high of $5.66 before sellers came in and pushed the shares back below the $5.00 level. Analysts have given ACHN stock a price target of $6.75.

ACHN stock chart:

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)
Six month stock price chart for Achillion ACHN

Achillion Pharmaceuticals Reports Interim Results

Achillion Pharmaceuticals released interim data from ongoing ACH-4471 trials that indicated the drug candidate had achieved clinically meaningful complement inhibition and demonstrated a favorable tolerability profile with no reports of clinically meaningful increases in liver enzymes. In this initial set of data, ACH-4471 improved LDH, hemoglobin, fatigue score, and other measures of response including PNH clone size. These interim results support Achillion’s global expansion plans for PNH clinical trials.

Achillion Pharmaceuticals Financial Report

For Q2 2017, Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) reported a net loss of (-$22.5) million or (-$0.16) per share, compared with a net loss of $18.5 million or $0.14 per share for the second quarter of 2016. Cash, cash equivalents, marketable securities, and interest receivable as of June 30, 2017 were $369.9 million. Research and development expenses were $18.3 million compared with $14.2 million for the same period of 2016. The increase was primarily due to increased ACH-4471 clinical trial costs as well as increased manufacturing costs for ACH-5228. SG&A expenses were $5.4 million, compared with $5.2 million for Q2 2016. The increase was primarily due to increased legal and consulting fees.

For the six months ended June 30, 2017, Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)’s net loss was $42.7 million, compared to a net loss of $36.6 million for the first half of 2016. R&D totaled $33.8 million, compared with $27.4 million for the same period in 2016.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ACHN and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

MannKind Corporation (NASDAQ:MNKD) Makes Announcement Ahead of Q2 Financial Release

MannKind Corporation (NASDAQ:MNKD)

MannKind Corporation (NASDAQ:MNKD) will be announcing their Q2 2017 financial report after the market closes today. However this morning, prior to the market open, Mannkind and One Drop announced that they have taken the initial step in their collaboration. The collaboration takes the form of a randomized controlled trial named A-ONE. A-ONE will investigate the use of Afrezza® inhaled insulin and One Drop’s integrated digital diabetes care platform. Shares in the pre-market are down 2.5% at $1.19 on light volume. Mannkind stock price chart:

MannKind Corporation (NASDAQ:MNKD)
Mannkind Stock Price Chart

MannKind Corporation (NASDAQ:MNKD) and One Drop announced a memorandum of understanding in May of 2017. The collaboration is intended to study One Drop’s Mobile app, One Drop Premium and Afrezza®, MannKind’s inhaled rapid-acting mealtime insulin. One Drop Premium is a bundling of One Drop’s Mobile app, Chrome meter and test strips, and Experts coaching service. One goal of the collaboration is to identify ways of simplifying the complexity of starting and staying on mealtime insulin along with Customized Coaching to help people afflicted with type 2 Diabetes achieve their A1C goals.

People with type 2 diabetes, who meet the inclusion criteria, will be randomly assigned one of two treatments – Afrezza® with One Drop Premium or, One Drop Premium alone. Changes in hemoglobin A1C, quality of life, self-care, treatment satisfaction, and other metrics will be assessed.

In its prior quarterly financial report, MannKind Corporation (NASDAQ:MNKD) reported a loss of $16 on $3 million in revenue. Losses, adjusted for non-recurring gains, came to (-$0.22) per share. However the market responded positively and shares gained almost 43% to end the day at $1.60. On Friday shares of MannKind Corporation (NASDAQ:MNKD) closed at $1.22.

After four consecutive years of losses, MannKind Corporation (NASDAQ:MNKD) posted a per share profit of $1.37 for 2016 on sales of $174.8 million. But, so far, investors have shunned the company’s shares and MNKD is down over 61% YTD, and down over 75% for the year. However, for the quarter, MNKD shares are up over 53%.

No doubt that traders will be paying close attention to this afternoon’s financial release as they try to determine if the company’s break-through diabetes treatment can bring performance to the bottom line.

MannKind Corporation (NASDAQ:MNKD) will release its Q2 2017 financial results on Monday, August 7, 2017 at 5:00 PM EST on August 7, 2017. To participate in the live call by telephone, dial (888) 771-4371 or (847) 585-4405 and enter the passcode: 44096373.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $MNKD and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Cerus Corporation (NASDAQ:CERS) Gets Credit and Stock Bump

Cerus Corporation (NASDAQ:CERS)

Cerus Corporation (NASDAQ:CERS) stock price gained over 7.6% after the company announced that it had entered into a $40 million amended growth capital credit facility. The credit facility is being provided by Oxford Finance LLC, a specialty finance firm that provides senior debt to life sciences and healthcare companies worldwide. The announcement of a new credit facility comes one day after Cerus announced the signing of two, new, expanded contracts with Établissement Français du Sang (EFS), the French National Blood Service, for the INTERCEPT Blood System. CERS stock ended the day at $2.39. CERS stock price chart:

Cerus Corporation (NASDAQ:CERS)
One month daily candlebar chart for CERS

Cerus Corporation (NASDAQ:CERS) is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens that may be present in donated blood. The nucleic acid targeting mechanism of action of the INTERCEPT treatment is designed to inactivate established transfusion threats, such as Hepatitis B and C, HIV, West Nile Virus and bacteria, as well as emerging pathogens such as chikungunya, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and globally.

Kevin D. Green, vice president, finance and chief financial officer of Cerus Corporation (NASDAQ:CERS) “Oxford continues to be an invaluable partner. Their appreciation of our business opportunity and shared belief in our mission to establish INTERCEPT as the standard of care for transfused blood components globally strengthens our relationship. The non-dilutive capital and potential access to additional proceeds provide us with financial flexibility to help us execute on our commercial growth strategy, as well as to support key clinical programs.”

Cerus Corporation (NASDAQ:CERS) stock is down over 45% YTD, and is down over 66% for the year. Three investment firms follow Cerus. All three rte CERS stock as a “Strong Buy”.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CERS and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.